Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE)
Health Care · Biotechnology · US
$15.28
-1.29% today · -51.7% 1Y
Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.52B and employs 1,371 people.
Over the last twelve months the share price has lost 51.7%, trading between 12.73 and 39.89.
Tweenvest scores Ultragenyx Pharmaceutical Inc. across four factors: quality 26/100, value 55/100, growth 88/100. Its strongest factor is growth.
RARE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.52B
- Revenue (TTM)
- $717.00M
- P/E
- —
- EPS
- -5.83
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- $39.89
- 52-week low
- $12.73
- Avg volume (3M)
- —
- Shares outstanding
- 98.29M
- Employees
- 1,371
- Next earnings
- —
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
- ISIN
- US90400D1081
- Founded
- 2010
- Listed since
- Jan 31, 2014
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| COMPASS Pathways plcNasdaqGS: CMPS | $1.66B | $11.59 | -3.46% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.60B | $24.45 | -1.17% |
| Mabwell (Shanghai) Bioscience Co., Ltd.SHSE: 688062 | $1.60B | CN¥24.78 | -8.36% |
| uniQure N.V.NasdaqGS: QURE | $1.57B | $21.52 | -4.74% |
| Shanghai OPM Biosciences Co., Ltd.SHSE: 688293 | $1.52B | CN¥71.50 | -10.19% |
| Syndax Pharmaceuticals, Inc.NasdaqGS: SNDX | $1.52B | $16.49 | -2.97% |
| Immunocore Holdings plcNasdaqGS: IMCR | $1.51B | $29.20 | -0.65% |
| Wedge Industrial Co.,Ltd.SZSE: 000534 | $1.50B | CN¥20.79 | -3.88% |
Figures last refreshed Oct 11, 2026.